CHUGAI - Hefty Price Cut on Actemra Owing to Exceeding Projected Sales - Slightly Negative!
MHLW’s new price cut listing that indicates Actemra will face ~25% price cut from April 2012. While this will increase Actemra’s penetration, the net impact is expected to be slightly negative. Apart from this, the overall impact of price cuts on Chugai is expected to be at par with industry i.e. ~6%.
The reason for this high price cut is due to higher than anticipated sales of Actemra than what Chugai had anticipated at the time of Actemra’s filing for RA (¥50b in 2018) – a regulatory requirement and one of the key basis on which Japanese companies negotiate NIH price of new drugs. Actemra has been very successful in RA since its launch in Japan in 2008 and remains a key growth driver for Chugai.
The reason for this high price cut is due to higher than anticipated sales of Actemra than what Chugai had anticipated at the time of Actemra’s filing for RA (¥50b in 2018) – a regulatory requirement and one of the key basis on which Japanese companies negotiate NIH price of new drugs. Actemra has been very successful in RA since its launch in Japan in 2008 and remains a key growth driver for Chugai.
COMPANIES MENTIONED
CHUGAI
CHUGAI
